---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-23-000178"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:52:12.003887+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CareDx Q2 2023 revenue $70.3M (-13% YoY); net loss $0.46 per share vs $0.41 loss last year

## Summary
- Testing services revenue $53.4M, down 20% YoY due to Medicare Billing Article revisions.
- Patient and Digital Solutions revenue $9.0M (+33% YoY); Products revenue $7.9M (+17% YoY).
- AlloMap and AlloSure test results ~37,500 (-17% YoY); over 80% adoption of new requisition forms.
- Received first multimodal MolDX approval for HeartCare and first dd-cfDNA MolDX approval for AlloSure Lung.
- Full year 2023 revenue guidance $240M-$260M; cash and equivalents $283M, no debt.

## SEC filing metadata
- accession: 0001217234-23-000178
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/0001217234-23-000178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/cdna-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-23-000178
- JSON: https://secwatch.observer/filing/0001217234-23-000178.json
- Plain text: https://secwatch.observer/filing/0001217234-23-000178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.